`
`First Named Inventor: Rhett Mead
`
`SCHIFFMAN
`
`Applicant: VISUS THERAPEUTICS,INC.
`
`Application No.: 18/250,921
`
`§371(c) Date: April 27, 2023
`
`Confirmation No.: 4791
`
`Art Unit: 1613
`
`Examiner: HUANG, GIGI GEORGIANA
`
`Atty. Docket: 4902.0110003
`
`
`
`Title: DEGRADANT COMPOUND AND COMPOSITIONS THEREOF(as amended)
`
`First Supplemental Information Disclosure Statement
`
`Mail Stop Amendment
`
`Commissioner for Patents
`PO Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`Listed on accompanying IDS Form PTO/SB/08borits equivalent are documents that may be
`
`considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in
`
`compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering
`
`on this First Supplemental Information Disclosure Statement is a continuation of the numbering in
`
`Applicant’s Information Disclosure Statement filed on November 28, 2023, in connection with the
`
`above-captioned application.
`
`Applicant has listed publication dates on the attached IDS Form based on information
`
`presently available to the undersigned. However, the listed publication dates should not be
`
`construed as an admission that the information wasactually published on the date indicated.
`
`Applicant reserves the right to establish the patentability of the claimed invention over any
`
`of the information provided herewith, and/or to prove that this information may notbe priorart,
`
`and/or to prove that this information may not be enabling for the teachings purportedly offered.
`
`
`
`-2-
`
`Rhett Mead SCHIFFMAN
`Application No.: 18/250,921
`
`This statement should not be construed as a representation that a search has been made, or
`
`that information more material to the examination of the present patent application does not exist.
`
`The Examineris specifically requested not to rely solely on the material submitted herewith.
`
`This is a filing under 37 C.F.R. § 1.97(b). This Information Disclosure Statementis being
`
`filed before the mailing date ofa first Office Action on the merits. No statementor fee is required.
`
`Copies of documents NPL8-NPL9are submitted.
`
`It is respectfully requested that the Examinerinitial and return a copy of the enclosed IDS
`
`Form, and indicate in the official file wrapper of this patent application that the documents have
`
`been considered.
`
`The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or
`
`credit any overpayment, to our Deposit Account No. 19-0036.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`/Marsha Rose Gillentine, Reg. No. 58,403/
`
`Marsha Rose Gillentine
`Attorney for Applicant
`Registration No. 58,403
`
`Date:__November4, 2024
`
`1101 K Street, NW
`10" Floor
`Washington, D.C. 20005
`Main: 202-371-2600
`Direct: 202-772-8692
`
`Atty. Dkt. No. 4902.0110003
`
`